A Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Objectives Despite efforts to identify characteristics associated with medication-placebo differences in antidepressant trials, few consistent findings have emerged to guide participant selection in drug development settings and differential therapeutics in clinical practice. Limitations in the methodologies used, particularly searching for a single moderator while treating all other variables as noise, may partially explain the failure to generate consistent results. The present study tested whether interactions between pre-treatment patient characteristics, rather than a single-variable solution, may better predict who is most likely to benefit from placebo vs. medication. Methods We analyzed data from 174 patients aged 75 years and older with unipolar depression who were randomly assigned to citalopram or placebo. We conducted model-based recursive partitioning analysis to identify the most robust significant moderators of placebo vs. citalopram response. Results The greatest signal detection between medication and placebo in favor of medication was among patients with fewer years of education (≤ 12) who suffered from a longer duration of depression since their first episode (> 3.47 years) (B=2.53, t(32)=3.01, p =.004). Compared to medication, placebo had the greatest response for those who were more educated (> 12 years), to the point where placebo almost outperformed medication (B=−0.57, t(96)=−1.90, p=.06). Conclusions Machine learning approaches capable of evaluating the contributions of multiple predictor variables may be a promising methodology for identifying placebo vs. medication responders. Duration of depression and education should be considered in the efforts to modulate placebo magnitude in drug development settings and in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Psychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109 · cited 1×
“The increase in trial failures observed in the past decades appears to be the result of rising placebo response rather than of declining medication response (3-4).”
BackgroundDeRubeis, R. J., Cohen, Z. D., Forand, N. R., Fournier, J. C., Gelfand, L. A., & Lorenzo-Luaces, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083875 · Cited by 509 · cited 3×
“Novel, systematic approaches to subgroup analysis have recently shown differential effects for different treatment conditions across patient subgroups (17-18).”
BackgroundMethodResultFava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069738 · Cited by 452 · cited 1×
“The fact that high placebo response hinders the development and eventual approval of new antidepressants has led most pharmaceutical companies and academic researchers to undertake initiatives aimed at reducing placebo response (9-11).”
BackgroundTreatment selection in depression.
Cohen, Z. D., & DeRubeis, R. J. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084746 · Cited by 435 · cited 1×
“The results of this study could inform the design of future phase III trials in drug development settings (49).”
BackgroundA Model of Placebo Response in Antidepressant Clinical Trials
Rutherford, B. R., & Roose, S. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040474 · Cited by 268
Self-citationBridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256 · cited 1×
“The increase in trial failures observed in the past decades appears to be the result of rising placebo response rather than of declining medication response (3-4).”
BackgroundNelson, J. C., Delucchi, K., & Schneider, L. S. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000308883.64832.ed · Cited by 230
Patient Expectancy as a Mediator of Placebo Effects in Antidepressant Clinical Trials
Rutherford, B. R., Wall, M. M., Brown, P. J., Choo, T.-H., Wager, T. D., Peterson, B. S., Chung, S., Kirsch, I., & Roose, S. P. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16020225 · Cited by 183 · cited 1×
“14 It is interesting to speculate whether expectancy effects, which have been shown to be important mediators of placebo effects in antidepressant trails (44), may partially explain the effects identified for education.”
BackgroundSelf-citation
Cited by
Artificial intelligence for mental health and mental illnesses: an overview
Graham, S., Depp, C., Lee, E. E., Nebeker, C., Tu, X., Kim, H.-C., & Jeste, D. V. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1094-0 · Cited by 970
A Scoping Review of Machine Learning in Psychotherapy Research
Aafjes-van Doorn, K., Kamsteeg, C., Bate, J., & Aafjes, M. (2021) · Psychotherapy Research · doi:10.1080/10503307.2020.1808729 · Cited by 179
Optimizing patient expectancy in the pharmacologic treatment of major depressive disorder
Zilcha-Mano, S., Brown, P. J., Roose, S. P., Cappetta, K., & Rutherford, B. R. (2019) · Psychological Medicine · doi:10.1017/s0033291718003343 · Cited by 29
Self-citationLebowitz, E. R., Zilcha‐Mano, S., Orbach, M., Shimshoni, Y., & Silverman, W. K. (2021) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13386 · Cited by 19
Self-citation
Metadata
- Authors
- Zilcha-Mano, S., Roose, S. P., Brown, P. J., & Rutherford, B. R.
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 26
- Issue
- 6
- Pages
- 669-677
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W2782556916
- Cited by
- 42
- References
- 12
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials. https://app.cochat.ai/papers/10.1016/j.jagp.2018.01.001
- The paper
- Zilcha-Mano, S., Roose, S. P., Brown, P. J., & Rutherford, B. R. (2018). A Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials. The American Journal of Geriatric Psychiatry. https://doi.org/10.1016/j.jagp.2018.01.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.